publication date: Feb. 26, 2016

Laurie Glimcher Named CEO of Dana-Farber 


LAURIE GLIMCHER was named president and CEO of the Dana-Farber Cancer Institute.

Glimcher is currently the Stephen and Suzanne Weiss Dean of the Medical College at Weill Cornell Medicine, and is also professor of medicine and provost for medical affairs at Cornell University.

“Dr. Glimcher is in many ways an ideal choice for Dana-Farber,” said Josh Bekenstein, chairman of the Dana-Farber Board of Trustees. “She is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. She has had extraordinary success as the leader of a major academic medical institution. Most importantly, she has a deep understanding of the latest developments in cancer research and care, and a clear vision of how Dana-Farber can most powerfully affect the fight against cancer.”

Glimcher will also serve as a professor of medicine at Harvard Medical School, as well as president of Dana-Farber/Partners Cancer Care, principal investigator of Dana-Farber/Harvard Cancer Center, and trustee of Dana-Farber/Boston Children’s Hospital Cancer Care.

Current President Edward Benz, Jr. has agreed to remain in the position until her arrival at the institute.

“It is an enormous honor and privilege to be chosen as the next leader of the Dana-Farber Cancer Institute,” said Glimcher. “The opportunity to advance Dana-Farber’s groundbreaking research and to improve the care available to patients with cancer is truly special to me, and I am thrilled to be returning home to Boston. Cancer research and care have reached a transformative moment in science, and I look … Continue reading 42-08 In Brief: Laurie Glimcher Named CEO of Dana-Farber

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.